Dexamethasone Palmitate for PONV After Craniotomy
Recruiting now · Not applicable
Conditions studied: Postoperative Nausea and Vomiting
In brief
Dexamethasone is almost one of the most commonly used drugs for postoperative nausea and vomiting (PONV) prevention. However, PONV is still a complex problem to be solved; for example, even with preoperative dexamethasone administration, there are still some patients undergoing craniotomy still experience PONV within 24 hours postoperatively. Compared to dexamethasone, dexamethasone palmitate has a long-lasting anti-inflammatory effect, 2-5 times that of traditional water-soluble dexamethasone, with fewer adverse effects. This trial aims to assess the effect and safety of preoperative dexamethasone palmitate on PONV after craniotomy.
Key facts
- Study ID
- NCT06988124
- Run by
- Beijing Tiantan Hospital
- People needed
- 500
- Starts
- 2025-06-25
- Expected to finish
- 2027-06-01
- Last updated by the study team
- 2025-09-23
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Aged 18 to 65 years;
- Providing written informed consent;
- Perform elective craniotomy undergoing general anesthesia.
You may not qualify if…
- Known to be allergic to dexamethasone;
- Any systemic glucocorticoids within 3 months before trial entry;
- History of severe heart disease, liver/kidney failure, or systemic rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, et al);
- Cognitive impairment or severe mental illness;
- Uncontrolled diabetes or infectious diseases;
- Pregnancy or breastfeeding.
Where it is running
- Fang Luo — Beijing, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.